Retatrutide
Retatrutide is the first triple hormone receptor agonist ever developed — activating GLP-1, GIP, and glucagon receptors simultaneously to produce weight loss, metabolic improvement, and osteoarthritis pain relief that no previous medication has achieved. Phase 3 clinical trials recorded an average of 28.7% body weight reduction at 68 weeks — roughly 71 pounds — alongside a 75.8% reduction in knee osteoarthritis pain scores. At Magnolia Functional Wellness, Dr. Farhan Abdullah will offer retatrutide as part of a physician-supervised metabolic health protocol upon FDA approval.